FDA.reportPublic FDA data

caffeine 100 MG / ergotamine tartrate 2 MG Rectal Suppository [Migergot]

RxCUI
1293639
RxNorm name
caffeine 100 MG / ergotamine tartrate 2 MG Rectal Suppository [Migergot]
Display name
MIGERGOT (Rectal)
Full name
caffeine 100 MG / ergotamine tartrate 2 MG Rectal Suppository [Migergot]
Term type
SBD
Status
Active
Strength
100-2 mg
Dose form
Suppository
Route
Rectal
Updated
2026-10-29 06:02:13

RxNorm Status History#

Status
Active
Source
RXNORM
Current
YES
Release start
062012
Active start
062012
Multiple ingredient
YES
Branded
YES

Ingredients And Strength#

Ingredient, Strength, Base table
IngredientStrengthBaseBasis of strength
caffeine100 MG / 1 EACHcaffeinecaffeine
ergotamine tartrate2 MG / 1 EACHergotamineergotamine tartrate

Dose Form Concepts#

Dose form, RxCUI table
Dose formRxCUI
Rectal Suppository316978

Derived Ingredient Concepts#

Ingredient, RxCUI table
IngredientRxCUI
caffeine1886
ergotamine4025

Source Vocabulary Codes#

Code type, Values, Count table
Code typeValuesCountCategory
PRESCRIBABLEY1ATTRIBUTES
RXNAV_STRMigergot (caffeine 100 MG / ergotamine tartrate 2 MG) Rectal Suppository1NAMES
RxNorm Namecaffeine 100 MG / ergotamine tartrate 2 MG Rectal Suppository [Migergot]1NAMES
RxNorm SynonymMigergot (caffeine 100 MG / ergotamine tartrate 2 MG) Rectal Suppository1NAMES
TTYSBD1ATTRIBUTES
SPL_SET_ID3a31ad0c-7bdd-544b-f5df-a99d04cf541c1CODES
RxCUI12936391CODES
MMSL_CODEBD14511CODES

FDA NDC Products And Packages#

Package NDC, Product NDC, Name table
Package NDCProduct NDCNameLabelerApplication
0713-0166-120713-0166MIGERGOT Ergotamine Tartrate and CaffeineCosette Pharmaceuticals, Inc.ANDA086557

Drugs@FDA Applications#

Application, NDC, Name table
ApplicationNDCNameMarketing categoryLabeler
ANDA0865570713-0166MIGERGOT Ergotamine Tartrate and CaffeineANDACosette Pharmaceuticals, Inc.

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 4 matching rows.

NDC11, Source, Active table
NDC11SourceActive
00713016612rxnav_ndcsyes
00713016606rxnav_historical
60809016612rxnav_historical
75987009011rxnav_historical

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
MIGERGOTERGOTAMINE TARTRATE AND CAFFEINECosette Pharmaceuticals, Inc.3a31ad0c-7bdd-544b-f5df-a99d04cf541c2022-11-29Boxed warning, Warnings, Adverse reactionsExact identifier
ndc (package): 0713-0166-12
ndc (product): 0713-0166
ndc11 (package): 00713016612
rxcui: 1293639

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 2 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
3a31ad0c-7bdd-544b-f5df-a99d04cf541cMIGERGOT 2 MG / 100 MG Rectal Suppository [PSN] · caffeine 100 MG / ergotamine tartrate 2 MG Rectal Suppository [Migergot] [SBD] · Migergot (caffeine 100 MG / ergotamine tartrate 2 MG) Rectal Suppository [SY]37ERGOTAMINE TARTRATE and CAFFEINE SUPPOSITORIES USP (For Rectal Administration) Rx only20221129
4ae331e0-009a-477e-8408-6118dc620634MIGERGOT 2 MG / 100 MG Rectal Suppository [PSN] · caffeine 100 MG / ergotamine tartrate 2 MG Rectal Suppository [Migergot] [SBD] · Migergot (caffeine 100 MG / ergotamine tartrate 2 MG) Rectal Suppository [SY]32Ergotamine Tartrate and Caffeine Suppositories USP20180130

Recently Linked DailyMed Labels#

Set ID, Title, Manufacturer table
Set IDTitleManufacturerEffective
3a31ad0c-7bdd-544b-f5df-a99d04cf541cERGOTAMINE TARTRATE and CAFFEINE SUPPOSITORIES USP (For Rectal Administration) Rx onlyCosette Pharmaceuticals, Inc. | Cosette Pharmaceuticals NC Laboratories, LLC20221129
4ae331e0-009a-477e-8408-6118dc620634Ergotamine Tartrate and Caffeine Suppositories USPHorizon Pharma Inc.20180130
90dd6ccc-d5ad-4c1b-af6c-13478da565b1National Council for Prescription Drug Programs20120724

Drug Classes#

Source, Class ID, Class table
SourceClass IDClassTypeRelationshipDrug concept
ATCN02CAErgot alkaloidsATC1-4ergotamine
ATCD11AXOther dermatologicalsATC1-4caffeine
ATCN06BCXanthine derivativesATC1-4caffeine
FDASPLD004879ErgotaminesCHEMhas_chemical_structureergotamine
FDASPLD014970XanthinesCHEMhas_chemical_structurecaffeine
FDASPLN0000175739Central Nervous System StimulantEPChas_epccaffeine
FDASPLN0000175766Ergotamine DerivativeEPChas_epcergotamine
FDASPLN0000175790MethylxanthineEPChas_epccaffeine
FDASPLN0000175729Central Nervous System StimulationPEhas_pecaffeine
MEDRTD001393AzolesCHEMci_chemclassergotamine tartrate
MEDRTD001393AzolesCHEMci_chemclassergotamine
MEDRTD002110CaffeineCHEMhas_ingredientcaffeine
MEDRTD002219CarbamatesCHEMci_chemclassergotamine tartrate
MEDRTD004878ErgotamineCHEMhas_ingredientergotamine
MEDRTD004878ErgotamineCHEMhas_ingredientergotamine tartrate
MEDRTD005663FuransCHEMci_chemclassergotamine tartrate
MEDRTD018942MacrolidesCHEMci_chemclassergotamine tartrate
MEDRTD018942MacrolidesCHEMci_chemclassergotamine
MEDRTD019888NelfinavirCHEMci_chemclassergotamine tartrate
MEDRTD019438RitonavirCHEMci_chemclassergotamine tartrate
MEDRTD013449SulfonamidesCHEMci_chemclassergotamine tartrate
MEDRTD000033Abortion, ThreatenedDISEASEci_withergotamine tartrate
MEDRTD000788Angina Pectoris, VariantDISEASEmay_diagnoseergotamine tartrate
MEDRTD001049ApneaDISEASEmay_treatcaffeine
MEDRTD003027Cluster HeadacheDISEASEmay_treatergotamine tartrate
MEDRTD003027Cluster HeadacheDISEASEmay_treatergotamine
MEDRTD003327Coronary DiseaseDISEASEci_withergotamine tartrate
MEDRTD003327Coronary DiseaseDISEASEci_withergotamine
MEDRTD004342Drug HypersensitivityDISEASEci_withergotamine tartrate
MEDRTD004342Drug HypersensitivityDISEASEci_withergotamine
MEDRTD004342Drug HypersensitivityDISEASEci_withcaffeine
MEDRTD005221FatigueDISEASEmay_treatcaffeine
MEDRTD006973HypertensionDISEASEci_withergotamine
MEDRTD006973HypertensionDISEASEci_withergotamine tartrate
MEDRTD007674Kidney DiseasesDISEASEci_withergotamine tartrate
MEDRTD007674Kidney DiseasesDISEASEci_withergotamine
MEDRTD008107Liver DiseasesDISEASEci_withergotamine
MEDRTD008107Liver DiseasesDISEASEci_withergotamine tartrate
MEDRTD008881Migraine DisordersDISEASEmay_treatergotamine tartrate
MEDRTD008881Migraine DisordersDISEASEmay_treatergotamine
MEDRTD016491Peripheral Vascular DiseasesDISEASEci_withergotamine tartrate
MEDRTD016491Peripheral Vascular DiseasesDISEASEci_withergotamine
MEDRTD006473Postpartum HemorrhageDISEASEmay_preventergotamine tartrate
MEDRTD006473Postpartum HemorrhageDISEASEmay_treatergotamine tartrate
MEDRTD011247PregnancyDISEASEci_withergotamine tartrate
MEDRTD011247PregnancyDISEASEci_withergotamine
MEDRTD018805SepsisDISEASEci_withergotamine tartrate
MEDRTD018805SepsisDISEASEci_withergotamine
MEDRTN0000000209Adrenergic alpha-AgonistsMOAhas_moaergotamine
MEDRTN0000000209Adrenergic alpha-AgonistsMOAhas_moaergotamine tartrate
MEDRTN0000190114Cytochrome P450 3A InhibitorsMOAhas_moaergotamine tartrate
MEDRTN0000190114Cytochrome P450 3A InhibitorsMOAhas_moaergotamine
MEDRTN0000182141Cytochrome P450 3A4 InhibitorsMOAci_moaergotamine
MEDRTN0000182141Cytochrome P450 3A4 InhibitorsMOAci_moaergotamine tartrate
MEDRTN0000000203Dopamine Receptor InteractionsMOAhas_moaergotamine tartrate
MEDRTN0000000203Dopamine Receptor InteractionsMOAhas_moaergotamine
MEDRTN0000000133Enzyme InhibitorsMOAhas_moacaffeine
MEDRTN0000000130Serotonin AntagonistsMOAhas_moaergotamine
MEDRTN0000000130Serotonin AntagonistsMOAhas_moaergotamine tartrate
MEDRTN0000008322BronchodilationPEhas_pecaffeine
MEDRTN0000008331Cardiovascular Activity AlterationPEhas_pecaffeine
MEDRTN0000008351Cerebral Arterial VasoconstrictionPEhas_peergotamine
MEDRTN0000008351Cerebral Arterial VasoconstrictionPEhas_peergotamine tartrate
MEDRTN0000008376Cutaneous Arterial VasoconstrictionPEhas_peergotamine tartrate
MEDRTN0000008567Decreased Collecting Duct Water PermeabilityPEhas_pecaffeine
MEDRTN0000009197Increased Central Nervous System Organized Electrical ActivityPEhas_pecaffeine
MEDRTN0000009705Increased Uterine Smooth Muscle Contraction or TonePEhas_peergotamine tartrate
MEDRTN0000009705Increased Uterine Smooth Muscle Contraction or TonePEhas_peergotamine

Properties#

Category, Property, Value table
CategoryPropertyValue
ATTRIBUTESAVAILABLE_STRENGTH100 MG / 2 MG
ATTRIBUTESGENERAL_CARDINALITYMULTI
ATTRIBUTESHUMAN_DRUGUS
ATTRIBUTESRXNAV_HUMAN_DRUGUS
ATTRIBUTESSCHEDULE0
CODESANDAANDA086557
NAMESPrescribable SynonymMIGERGOT 2 MG / 100 MG Rectal Suppository
SOURCESSourceGold Standard Alchemy
SOURCESSourceMetathesaurus FDA Structured Product Labels
SOURCESSourceMicromedex RED BOOK
SOURCESSourceMultum MediSource Lexicon